**Nimenrix® (meningococcal groups A, C, W-135 and Y conjugate vaccine) eModule Series for Healthcare Professionals**

**Module 1 – Knowledge Check**

1. Meningococcal meningitis can progress quickly. How long after the onset of symptoms can it become fatal?
	1. 1 hour
	2. 24 to 48 hours
	3. 2 weeks
	4. 2 months

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. True or false: The majority of people exposed to the *Neisseria meningitidis* bacteria develop invasive meningococcal disease.

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. True or false: *Neisseria meningitidis* bacteria can overcome host defences of the throat and nose and enter the bloodstream.

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. The meninges are membranes that surround…
	1. The lungs
	2. The brain and spinal cord
	3. The heart
	4. The intestines

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. In England, what percentage of patients with invasive meningococcal disease clinically presented with both meningitis and septicaemia?
	1. 26.1%
	2. 45.6%
	3. 21.2%
	4. 4.5%

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. *Neisseria meningitidis* bacteria can infect…
	1. Humans only
	2. Animals only
	3. Humans and animals
	4. Neither humans nor animals

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. True or false: *Neisseria meningitidis* can be spread through airborne droplets or direct contact with respiratory secretions or saliva.

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. Which of the following are known host risk factors for invasive meningococcal disease? *Select all that apply*
	1. Age, infants, young children, and adolescents
	2. Absence or abnormal function of the spleen
	3. Complement disorders
	4. Respiratory tract infections

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. Which of the following are known environmental risk factors for invasive meningococcal disease? *Select all that apply*
	1. Active and passive smoking
	2. Crowded living conditions
	3. Closed populations (e.g., Hajj pilgrims)

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

1. Most cases of invasive meningococcal disease are caused by which serogroups of *Neisseria meningitidis*?
	1. A and B
	2. A, B, C, W-135, X and Y
	3. E and X
	4. X and Y

ANSWER\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**ANSWERS**

1. Meningococcal meningitis can progress quickly. How long after the onset of symptoms can it become fatal?
	1. 1 hour
	2. 24 to 48 hours
	3. 2 weeks
	4. 2 months

Answer: b1

1. True or false: The majority of people exposed to the *Neisseria meningitidis* bacteria develop invasive meningococcal disease.

Answer: False2

1. True or false: *Neisseria meningitidis* bacteria can overcome host defences of the throat and nose and enter the bloodstream.

Answer: True2

1. The meninges are membranes that surround…
	1. The lungs
	2. The brain and spinal cord
	3. The heart
	4. The intestines

 Answer: b3

1. In England, what percentage of patients with invasive meningococcal disease clinically presented with both meningitis and septicaemia?
	1. 26.1%
	2. 45.6%
	3. 21.2%
	4. 4.5%

 Answer: c4

1. *Neisseria meningitidis* bacteria can infect…
	1. Humans only
	2. Animals only
	3. Humans and animals
	4. Neither humans nor animals

Answer: a5

1. True or false: *Neisseria meningitidis* can be spread through airborne droplets or direct contact with respiratory secretions or saliva.

Answer: True6

1. Which of the following are known host risk factors for invasive meningococcal disease? *Select all that apply*
	1. Age, infants, young children, and adolescents
	2. Absence or abnormal function of the spleen
	3. Complement disorders
	4. Respiratory tract infections

 Answer: a, b, c, d2, 7, 8

1. Which of the following are known environmental risk factors for invasive meningococcal disease? *Select all that apply*
	1. Active and passive smoking
	2. Crowded living conditions
	3. Closed populations (e.g., Hajj pilgrims)

 Answer: a, b, c 2, 8

1. Most cases of invasive meningococcal disease are caused by which serogroups of *Neisseria meningitidis*?
	1. A and B
	2. A, B, C, W-135, X and Y
	3. E and X
	4. X and Y

Answer: b9

**References**

1. WHO. Media centre: Meningococcal meningitis Fact sheet Available at: <http://www.who.int/mediacentre/factsheets/fs141/en/> Accessed June 2021.

2. Rosenstein NE, Perkins BA, Stephens DS, *et al*. Meningococcal disease. *N Engl J Med* 2001;344(18):1378–1388.

3. Meningitis Research Foundation. Meningitis: Frequently asked questions. Available from: <https://www.meningitis.org/meningitis/frequently-asked-questions>. Accessed June 2021.

4. Parikh S, Campbell H, Gray S, et al. Epidemiology, clinical presentation, risk factors, intensive care admission and outcomes of invasive meningococcal disease in England, 2010-2015. *Vaccine* 2018;36:3876-3881.

5. Van Deuren M, Brandtzaeg P, Van Der Meer JWM. Update on Meningococcal Disease with Emphasis on Pathogenesis and Clinical Management. *Clin Microbiol Rev* 2000;13(1):144–166.

6. Granoff DM, Harrison LH, Borrow R. Meningococcal vaccines. In: Plotkin (ed). Vaccines: Elsevier.

7. ­­Public Health England. Green Book. Chapter 22. Available from: <https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/554011/Green_Book_Chapter_22.pdf> Accessed June 2021.

8. Stephens DS. Conquering the meningococcus. *FEMS Microbiol Rev* 2007;31:3–14.

9. NaTHNaC. Travel Health Pro. Meningococcal Disease. <https://travelhealthpro.org.uk/factsheet/42/meningococcal-disease> Accessed June 2021.

